ReviewTrends in cancer2021
Computing the Role of Alternative Splicing in Cancer.
Review in Trends in cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 45 citations in OpenAlex.
- ASPIRE: Accurate alternative splicing prediction from limited RNA sequencing data and a minimal gene set.PLoS computational biology · 2026Article
- Advances and challenges of splicing prediction with AI.Nature genetics · 2026Review
- Long non-coding RNA H19 transported by colorectal cancer small extracellular vesicles promotes alternative splicing in healthy hepatocytes: new insights on liver pre-metastatic niche formation.Cell communication and signaling : CCS · 2026Article
- Unraveling the FGFR-RNA splicing axis: Mechanisms, oncogenic crosstalks and innovations for therapeutic purpose.Acta pharmaceutica Sinica. B · 2026Review
- Deciphering splicing heterogeneity at single-cell resolution by SCSES.Nature communications · 2025Article
- Integrative transcriptomic analysis reveals alternative splicing complexity and transcriptomic diversity in porcine placentas across altitudes.DNA research : an international journal for rapid publication of reports on genes and genomes · 2025Article
- Establishment of an alternative splicing prognostic risk model and identification of FN1 as a potential biomarker in glioblastoma multiforme.Scientific reports · 2025Article
- Splicing diversity enhances the molecular classification of pituitary neuroendocrine tumors.Nature communications · 2025Article
- Cyperotundone promotes chemosensitivity of breast cancer via SRSF1.Frontiers in pharmacology · 2025Article
- Neoantigen-based immunotherapy: advancing precision medicine in cancer and glioblastoma treatment through discovery and innovation.Exploration of targeted anti-tumor therapy · 2025Review
- Multi-omics landscape of alternative splicing in diffuse midline glioma reveals immune- and neural-driven subtypes with implications for spliceosome-targeted therapy.Frontiers in immunology · 2025Article
- Analysis of SLC genes alternative splicing identifies the SLC7A6 RI isoform as a therapeutic target for colorectal cancer.Cancer science · 2025Article
- SPLASH2 provides ultra-efficient, scalable, and unsupervised discovery on raw sequencing reads.bioRxiv : the preprint server for biology · 2024Article
- Alternative splicing regulation and its therapeutic potential in bladder cancer.Frontiers in oncology · 2024Review
- Long-read sequencing reveals the landscape of aberrant alternative splicing and novel therapeutic target in colorectal cancer.Genome medicine · 2023Article
- Comprehensively analysis of splicing factors to construct prognosis prediction classifier in prostate cancer.Journal of cellular and molecular medicine · 2023Article
- PHF5A regulates the expression of the DOCK5 variant to promote HNSCC progression through p38 MAPK activation.Biology direct · 2023Article
- ASCancer Atlas: a comprehensive knowledgebase of alternative splicing in human cancers.Nucleic acids research · 2023Article
- Targeting alternative splicing in cancer immunotherapy.Frontiers in cell and developmental biology · 2023Review
- A new molecular subclassification andFrontiers in pharmacology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Most human genes undergo alternative splicing (AS), and dysregulation of alternative splicing contributes to tumor initiation and progression. Computational analysis of genomic and transcriptomic data enables the systematic characterization of alternative splicing and its functional role in cancer. In this review, we summarize the latest computational approaches to studying alternative splicing in cancer and the current limitations of the most popular tools in this field. Finally, we describe some of the current computational challenges in the characterization of the role of alternative splicing in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.